Luis Alfonso
Gurpide Ayarra
Consultor Médico
Centro de Investigación Biomédica en Red de Cáncer
Madrid, EspañaCentro de Investigación Biomédica en Red de Cáncer-ko ikertzaileekin lankidetzan egindako argitalpenak (8)
2022
-
YES1 Is a Druggable Oncogenic Target in SCLC
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403
2021
2020
-
Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients
Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348
2019
-
Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer
International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001
-
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Nature Medicine, Vol. 25, Núm. 3, pp. 470-476
-
Programmed death–ligand 1 expression on direct Pap-stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens
Cancer Cytopathology, Vol. 127, Núm. 7, pp. 470-480
-
The dynamic use of EGFR mutation analysis in cell-free DNA as a follow-up biomarker during different treatment lines in non-small-cell lung cancer patients
Disease Markers, Vol. 2019
2017
-
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995